Verve Therapeutics has a total of 50 patents globally, out of which 1 have been granted. Of these 50 patents, more than 86% patents are active. Europe is where Verve Therapeutics has filed the maximum number of patents, followed by the United States of America and Canada. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Verve Therapeutics.
Verve Therapeutics was founded in 2018. The company Verve Therapeutics is a biotechnology company. To permanently lower a person’s risk of coronary artery disease, the company finds and creates medicines that safely modify the adult human genome. Do read about some of the most popular patents of Verve Therapeutics which have been covered by us in this article and also you can find Verve Therapeutics patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Verve Therapeutics patent portfolio.
How many patents does Verve Therapeutics have?
Verve Therapeutics has a total of 50 patents globally. These patents belong to 8 unique patent families. Out of 50 patents, 43 patents are active.
How Many Patents did Verve Therapeutics File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Verve Therapeutics Applications Filed | Verve Therapeutics Patents Granted |
| 2022 | 8 | – |
| 2021 | 42 | 1 |
How many Verve Therapeutics patents are Alive/Dead?
Worldwide Patents
How Many Patents did Verve Therapeutics File in Different Countries?
Countries in which Verve Therapeutics Filed Patents
| Country | Patent |
| Europe | 5 |
| United States Of America | 5 |
| Canada | 3 |
| Korea (South) | 3 |
| Australia | 3 |
| Brazil | 3 |
| New Zealand | 3 |
| Singapore | 3 |
| South Africa | 3 |
| United Kingdom | 3 |
| Israel | 3 |
| India | 2 |
| Malaysia | 1 |
| Mexico | 1 |
Where are Research Centers of Verve Therapeutics Patents Located?
List of Verve Therapeutics patents
| Verve Therapeutics Patent | Title |
| US11207416B2 | Compositions And Methods For Targeted Rna Delivery |
| US20230159926A1 | Base Editing Of Pcsk9 And Methods Of Using Same For Treatment Of Disease |
| US20230158174A1 | Chemically Modified Guide Rnas For Genome Editing With Cas9 |
| US20230134582A1 | Chemically Modified Guide Rnas For Genome Editing With Cas12B |
| US20220152210A1 | Compositions And Methods For Targeted Rna Delivery |
| EP4132951A2 | Chemically Modified Guide Rnas For Genome Editing With Cas12B |
| EP4133071A2 | Base Editing Of Angptl3 And Methods Of Using Same For Treatment Of Disease |
| EP4132591A2 | Base Editing Of Pcsk9 And Methods Of Using Same For Treatment Of Disease |
| EP4133072A2 | Chemically Modified Guide Rnas For Genome Editing With Cas9 |
| EP4114360A1 | Compositions And Methods For Targeted Rna Delivery |
| WO2023049299A3 | Gene Editing Of Pcsk9 Or Angptl3 And Compositions And Methods Of Using Same For Treatment Of Disease |
| WO2023015223A9 | Compositions And Methods For Targeted Rna Delivery |
| GB2613457A | Base Editing Of Angptl3 And Methods Of Using Same For Treatment Of Disease |
| GB2613225A | Compositions And Methods For Targeted Rna Delivery |
| GB2612452A | Base Editing Of Pcsk9 And Methods Of Using Same For Treatment Of Disease |
| BR112022020407A2 | Base Edition Of Pcsk9 And Methods Of Using It For Treatment Of Diseases |
| BR112022020428A2 | Base Edition Of Angptl3 And Methods Of Use The Same For Treatment Of Diseases |
| KR1020230016175A | Base Editing Of Angptl3 And Its Use For Disease Treatment |
| KR1020230016176A | Base Editing Of Pck9 And Its Use For Disease Treatment |
| KR1020230011913A | Compositions And Methods For Targeted Rna Delivery |
| IL297193A | Base Editing Of Pcsk9 And Methods Of Using Same For Treatment Of Disease |
| IL297194A | Base Editing Of Angptl3 And Methods Of Using Same For Treatment Of Disease |
| ZA202211851A | Base Editing Of Pcsk9 And Methods Of Using Same For Treatment Of Disease |
| ZA202211861A | Base Editing Of Angptl3 And Methods Of Using Same For Treatment Of Disease |
| SG11202253980QA | Base Editing Of Pcsk9 And Methods Of Using Same For Treatment Of Disease |
| SG11202253979JA | Base Editing Of Angptl3 And Methods Of Using Same For Treatment Of Disease |
| AU2021253959A1 | Base Editing Of Pcsk9 And Methods Of Using Same For Treatment Of Disease |
| AU2021252991A1 | Base Editing Of Angptl3 And Methods Of Using Same For Treatment Of Disease |
| BR112022017688A2 | Compositions And Methods For Targeted Rna Dispensation |
| IL296133A | Compositions And Methods For Targeted Rna Delivery |
| AU2021230367A1 | Compositions And Methods For Targeted Rna Delivery |
| SG11202252764TA | Compositions And Methods For Targeted Rna Delivery |
| ZA202210313A | Compositions And Methods For Targeted Rna Delivery |
| NZ793560A | Base Editing Of Angptl3 And Methods Of Using Same For Treatment Of Disease |
| NZ793530A | Base Editing Of Pcsk9 And Methods Of Using Same For Treatment Of Disease |
| CA3179863A1 | Base Editing Of Pcsk9 And Methods Of Using Same For Treatment Of Disease |
| CA3179862A1 | Base Editing Of Angptl3 And Methods Of Using Same For Treatment Of Disease |
| NZ792048A | Compositions And Methods For Targeted Rna Delivery |
| CA3174708A1 | Compositions And Methods For Targeted Rna Delivery |
| IN202217063383A | Base Editing Of Angptl3 And Methods Of Using Same For Treatment Of Disease |
| IN202217063035A | Base Editing Of Pcsk9 And Methods Of Using Same For Treatment Of Disease |
| MX2022010980A | Compositions And Methods For Delivery Of Targeted Rna |
| MYPI2022005598A0 | – |
| WO2022060871A1 | Lipid Formulations For Gene Editing |
| WO2022051677A1 | Compositions And Methods For Capping Rnas |
| WO2021207712A3 | Base Editing Of Pcsk9 And Methods Of Using Same For Treatment Of Disease |
| WO2021207710A3 | Base Editing Of Angptl3 And Methods Of Using Same For Treatment Of Disease |
| WO2021207711A3 | Chemically Modified Guide Rnas For Genome Editing With Cas9 |
| WO2021207651A3 | Chemically Modified Guide Rnas For Genome Editing With Cas12B |
| WO2021178725A1 | Compositions And Methods For Targeted Rna Delivery |
What are Verve Therapeutics key innovation segments?
What Technologies are Covered by Verve Therapeutics?
The chart below distributes patents filed by Verve Therapeutics